目的探讨β-受体阻滞剂酒石酸美托洛尔治疗慢性充血性心力衰竭中的临床疗效。方法选择慢性充血性心力衰竭者45例,在常规强心、利尿、扩血管药物治疗的基础上,加用酒石酸美托洛尔治疗4周后,比较治疗前后患者的临床指标变化,评估其临床有...目的探讨β-受体阻滞剂酒石酸美托洛尔治疗慢性充血性心力衰竭中的临床疗效。方法选择慢性充血性心力衰竭者45例,在常规强心、利尿、扩血管药物治疗的基础上,加用酒石酸美托洛尔治疗4周后,比较治疗前后患者的临床指标变化,评估其临床有效性和安全性。结果 酒石酸美托洛尔对慢性充血性心力衰竭患者的心功能可明显改善,心率明显降低(100.13±12.45 vs 73.03±7.28)P<0.05,血压也降低。结论在常规抗心力衰竭药物治疗的基础上加用酒石酸美托洛尔可明显改善患者的心脏功能,提高患者的生存率。展开更多
Objective To explore the role of serum fibrotic indices including hyaluronic acid （HA）, procollagen type Ⅲ NH2-terminal peptide （PCIIIP）, and laminin （LN） in assessing the severity of myocardial fibrosis in chr...Objective To explore the role of serum fibrotic indices including hyaluronic acid （HA）, procollagen type Ⅲ NH2-terminal peptide （PCIIIP）, and laminin （LN） in assessing the severity of myocardial fibrosis in chronic congestive heart failure （CHF）. Methods Serum levels of HA, PCIIIP, and LN in 39 patients with CHF E [14 with New York Heart Association （NYHA） functional class II, 21 with class Ⅲ, 4 with class Ⅳ] and in 46 patients with NYHA functional class I were assessed by radioimmunoassay. Results The serum concentrations of HA, PCMP, and LN were 359.75 ± 84.59 μg/L, 77.88 ± 24. 67 μg/L, 86. 73 ± 23.90 μg/L in CHF group, and 211.60 ±54. 80 μg/L, 64.82 ±23.99 μg/L, 82. 26 ±23.98 μg/L in NYHA functional class Ⅰ group, respectively. The HA level was significantly higher in CHF patients as compared with NYHA functional class Ⅰ group （ P 〈 0.05 ）. However, no difference was found in the levels of PCIIIP and LN between CHF group and NYHA functional class Ⅰ group. The serum HA concentration was negatively correlated with left ventricular ejection fraction （ r = - 0.71, P 〈 0.05 ）. Conclusion Serum HA level may act as an indicator for myocardial fibrosis.展开更多
Background: Recent data suggest that beta-blockers can be beneficial in patients with chronic heart failure (CHF). Atrial fibrillation (AF) is present in a significant number of patients with CHF and is associateing w...Background: Recent data suggest that beta-blockers can be beneficial in patients with chronic heart failure (CHF). Atrial fibrillation (AF) is present in a significant number of patients with CHF and is associateing with significant morbidity and increasing mortality rates. Thus it is necessary to establish therapy to improve the poor prognosis in this high-risk population, but a specific benefit of beta-blockers to the subset with concomitant AF and CHF has been little demonstrated. Objective: To examine the effects of Bisoprolol (6 months treatment) on the ventricular function and hemodynamics in patients with AF and CHF. Methods: 84 patients with stable CHF (NYHA≤Ⅲ class) and AF were assigned to Treated Group( n = 37) or Control group Ⅰ ( n = 22, 24-hour heart mean rate < 70/min) or Control Group Ⅱ ( n = 25, 24-hour heart mean rate ≥ 70/min) . All patients were given the basic therapy for CHF, and Treated Group received Bisopolol. Clinical and echocardiographic variables were measured in 3 groups at baseline and after 6 months, and the results were compared . Results: After 6 months of treatment with Bisoprolol, left ventricular ejection fraction (LVEF) and NYHA class had significandy improved (P < 0.05), and a trend towards a reduction in combined end point of death or CHF hospitalization was also observed (P < 0.20) in Treated Group; The increase of LVEF in Treated Group were associated with a reduction in mitral regurgitation degree and left atrial volume; The heart rate in mean 24-hour and at peak exercise decreased in Treated Group, but were similar to that in Control Group Ⅰ. Conclusion: 6 months of Bisoprolol therapy resulted in an improvement in the NYHA class and LVEF, and also showed a trend towards a reduction in hospitalization or death. The beneficial effects of Bisoprolol on patients with AF and CHF may be partly mediated by improvement of ventricular diastolic function.展开更多
Objective： To analyze the clinical characteristics and medical treatment of hospitalized patients with chronic heartfailure, and provide medication for the patients. Methods： According to medical records of inpatien...Objective： To analyze the clinical characteristics and medical treatment of hospitalized patients with chronic heartfailure, and provide medication for the patients. Methods： According to medical records of inpatients, demographicinformation, etiology, clinical features and treatment information were collected. Results： A total of 610 cases withheart failure from our hospital between July 2010 and June 2016 were analyzed. The average age of all the patientswas 63. Males accounted for 50.49%. There were 82.7% patients with NYHA functional classification at III-IV.31.3% patients with coronary artery disease, 28.4% with rheumatic heart diseases and 21.8% with expansion ofheart disease. 27.4 percent of the patients with the left ventricular ejection fraction lower than 40%. There were78.9% patients received aldosterone antagonist treatment, 63.4% received ACEI/ARB, 62.1% received digoxin,59.8% received beta blockers, and 75.4% patients received decoction, and 80.8% received Chinese patent medicine.Conclusion： The study has shown that high utilization of traditional Chinese medicine is to highlight theadvantages of the combination of traditional Chinese and western medicine in the treatment of heart failure. Theusage of spironolactone, ACEI/ARB, beta blockers in our hospital was lower than the ratio reported, higher thanthat of the national average. However, the use of diureticis is lower than that of national average, which may relateto the use of damp-clearing herbs. Clinicians should pay attention to the high utilization rate of digoxin. Patientswith the left ventricular ejection fraction 〉 50% accounted for 61.1%, which required more attention should be paidto the diagnosis and treatment of patients with heart failure of the ejection fraction remains.展开更多
Objective： To carry out a systematic evaluation of the efficacy of modified Zhenwu Decoction combined withwestern medicine in the treatment of heart failure. Methods： Literature was retrieved in China KnowledgeResou...Objective： To carry out a systematic evaluation of the efficacy of modified Zhenwu Decoction combined withwestern medicine in the treatment of heart failure. Methods： Literature was retrieved in China KnowledgeResource Integrated Database （CNKI）, Chinese scientific journal database （VIP）, Wanfang Data Resource System（WANFANG DATA）, PubMed and other traditional Chinese medicine related periodicals by retrieval methods ofsubject terms combined with free words and computer retrieval combined with manual retrieval. Literature wasscreened strictly according to the inclusion criteria.The quality of the included literature was evaluated according tothe quality standard of Jadad scale and Cochrane collaboration network bias risk assessment tool. The literaturedata was extracted. RevMan5.3 software was used to analyze data and the curative effect of modified ZhenwuDecoction combined with western medicine was objectively evaluated. Results： The response rate of theexperimental group was better than that of the control group [OR = 3.69,95% IC （2.36,5.79）]. The value of EF inthe experimental group was higher than that in the control group after treatment [MD = 5.85, 95% IC （3.90, 7.79） ].The Lee, score of the experimental group was lower than that of the control group after treatment [MD = -1.37,95% IC （-2.23, -0.52） ]. The value of BNP in the experimental group was less than that in the control group aftertreatment [MD = -114.48, 95%IC （-186.28, -42.68）]. The life quality score in the experimental group was less thanthat of the control group after treatment [MD = -8.44, 95%IC （-11.73, -5.15）]. Conclusion： The curative effect ofmodified Zhenwu Decoction combined with western medicine in the treatment of heart failure is better than thesimple western medicine treatment.So modified Zhenwu Decoction combined with western medicine in thetreatment of heart failure is worthy of clinical promotion. However, the results of this study still need further validation by more high quality randomized double blind controlled clinical trial because the overall quality of theresearch included.展开更多
Objective To study the urinary excretion of aquaporin-2 (AQP2) water channel protein, and the relationship between urine AQP2 concentration and renal AQP2 gene expression in chronic heart failure (CHF) rats. Methods...Objective To study the urinary excretion of aquaporin-2 (AQP2) water channel protein, and the relationship between urine AQP2 concentration and renal AQP2 gene expression in chronic heart failure (CHF) rats. Methods Male Sprague-Dawley rats (200?g-250?g) underwent either a left coronary artery ligation, a model of CHF, or a sham-operation. Nine weeks after surgery, urinary AQP2 concentrations and renal AQP2 protein levels were measured by Western blot. Results The urinary concentration of AQP2 water channel protein increased significantly in CHF rats as compared with sham-operated rats (365.6%±102.9% vs 98.5%±47.6%, P<0.01). There was positive correlation between urinary AQP2 concentration and renal AQP2 protein expression (r=0.89, P<0.01). Conclusion The urinary concentration of AQP2 water channel protein increases significantly in chronic heart failure rats.展开更多
In the present study, we aimed to explore the mechanism of Fu-Zi Decoction in the treatment of chronic heart failure(CHF) using network pharmacology. Sym Map database was used to analyze the modern medical(MM) symptom...In the present study, we aimed to explore the mechanism of Fu-Zi Decoction in the treatment of chronic heart failure(CHF) using network pharmacology. Sym Map database was used to analyze the modern medical(MM) symptoms of various medicines. The chemical components of Fu-Zi Decoction were obtained through TCMSP, ETCM database, and previous results. The targets of Fu-Zi Decoction were obtained through STITCH, Swiss Target Prediction, Target NET database, and literature. The targets for the treatment of CHF were obtained from the Dis Ge NET, GEO, and Drug Bank databases, and the common parts of the Fu-Zi Decoction targets were screened out to construct the PPI network. The PPI network was decomposed modularly, its functions were analyzed, and the KEGG pathway enrichment analysis was performed. The key target was verified by Swiss Dock for molecular docking. A total of 205 chemical components of Fu-Zi Decoction, 551 drug targets, and 521 disease targets were collected. Functional enrichment analysis revealed that it was mainly involved in biological processes, such as negative regulation of cell death, oxidative stress, and G protein-coupled receptor regulation. KEGG enrichment findings mainly involved fluid shear stress and atherosclerosis, IL-17 signaling pathway, and so on. The results of molecular docking showed that benzoylaconitine, aconitine, mesaconitine, paeoniflorin, and atractylodes Ⅲ all had a strong affinity with the core target CXCL8, suggesting that Fu-Zi Decoction could negatively regulate cell apoptosis and oxidative stress through fluid shear stress and atherosclerosis, IL-17 signaling pathway, and so on. Collectively, our data showed that Fu-Zi Decoction had a good effect on the treatment of CHF.展开更多
文摘目的探讨β-受体阻滞剂酒石酸美托洛尔治疗慢性充血性心力衰竭中的临床疗效。方法选择慢性充血性心力衰竭者45例,在常规强心、利尿、扩血管药物治疗的基础上,加用酒石酸美托洛尔治疗4周后,比较治疗前后患者的临床指标变化,评估其临床有效性和安全性。结果 酒石酸美托洛尔对慢性充血性心力衰竭患者的心功能可明显改善,心率明显降低(100.13±12.45 vs 73.03±7.28)P<0.05,血压也降低。结论在常规抗心力衰竭药物治疗的基础上加用酒石酸美托洛尔可明显改善患者的心脏功能,提高患者的生存率。
文摘Objective To explore the role of serum fibrotic indices including hyaluronic acid （HA）, procollagen type Ⅲ NH2-terminal peptide （PCIIIP）, and laminin （LN） in assessing the severity of myocardial fibrosis in chronic congestive heart failure （CHF）. Methods Serum levels of HA, PCIIIP, and LN in 39 patients with CHF E [14 with New York Heart Association （NYHA） functional class II, 21 with class Ⅲ, 4 with class Ⅳ] and in 46 patients with NYHA functional class I were assessed by radioimmunoassay. Results The serum concentrations of HA, PCMP, and LN were 359.75 ± 84.59 μg/L, 77.88 ± 24. 67 μg/L, 86. 73 ± 23.90 μg/L in CHF group, and 211.60 ±54. 80 μg/L, 64.82 ±23.99 μg/L, 82. 26 ±23.98 μg/L in NYHA functional class Ⅰ group, respectively. The HA level was significantly higher in CHF patients as compared with NYHA functional class Ⅰ group （ P 〈 0.05 ）. However, no difference was found in the levels of PCIIIP and LN between CHF group and NYHA functional class Ⅰ group. The serum HA concentration was negatively correlated with left ventricular ejection fraction （ r = - 0.71, P 〈 0.05 ）. Conclusion Serum HA level may act as an indicator for myocardial fibrosis.
文摘Background: Recent data suggest that beta-blockers can be beneficial in patients with chronic heart failure (CHF). Atrial fibrillation (AF) is present in a significant number of patients with CHF and is associateing with significant morbidity and increasing mortality rates. Thus it is necessary to establish therapy to improve the poor prognosis in this high-risk population, but a specific benefit of beta-blockers to the subset with concomitant AF and CHF has been little demonstrated. Objective: To examine the effects of Bisoprolol (6 months treatment) on the ventricular function and hemodynamics in patients with AF and CHF. Methods: 84 patients with stable CHF (NYHA≤Ⅲ class) and AF were assigned to Treated Group( n = 37) or Control group Ⅰ ( n = 22, 24-hour heart mean rate < 70/min) or Control Group Ⅱ ( n = 25, 24-hour heart mean rate ≥ 70/min) . All patients were given the basic therapy for CHF, and Treated Group received Bisopolol. Clinical and echocardiographic variables were measured in 3 groups at baseline and after 6 months, and the results were compared . Results: After 6 months of treatment with Bisoprolol, left ventricular ejection fraction (LVEF) and NYHA class had significandy improved (P < 0.05), and a trend towards a reduction in combined end point of death or CHF hospitalization was also observed (P < 0.20) in Treated Group; The increase of LVEF in Treated Group were associated with a reduction in mitral regurgitation degree and left atrial volume; The heart rate in mean 24-hour and at peak exercise decreased in Treated Group, but were similar to that in Control Group Ⅰ. Conclusion: 6 months of Bisoprolol therapy resulted in an improvement in the NYHA class and LVEF, and also showed a trend towards a reduction in hospitalization or death. The beneficial effects of Bisoprolol on patients with AF and CHF may be partly mediated by improvement of ventricular diastolic function.
文摘Objective： To analyze the clinical characteristics and medical treatment of hospitalized patients with chronic heartfailure, and provide medication for the patients. Methods： According to medical records of inpatients, demographicinformation, etiology, clinical features and treatment information were collected. Results： A total of 610 cases withheart failure from our hospital between July 2010 and June 2016 were analyzed. The average age of all the patientswas 63. Males accounted for 50.49%. There were 82.7% patients with NYHA functional classification at III-IV.31.3% patients with coronary artery disease, 28.4% with rheumatic heart diseases and 21.8% with expansion ofheart disease. 27.4 percent of the patients with the left ventricular ejection fraction lower than 40%. There were78.9% patients received aldosterone antagonist treatment, 63.4% received ACEI/ARB, 62.1% received digoxin,59.8% received beta blockers, and 75.4% patients received decoction, and 80.8% received Chinese patent medicine.Conclusion： The study has shown that high utilization of traditional Chinese medicine is to highlight theadvantages of the combination of traditional Chinese and western medicine in the treatment of heart failure. Theusage of spironolactone, ACEI/ARB, beta blockers in our hospital was lower than the ratio reported, higher thanthat of the national average. However, the use of diureticis is lower than that of national average, which may relateto the use of damp-clearing herbs. Clinicians should pay attention to the high utilization rate of digoxin. Patientswith the left ventricular ejection fraction 〉 50% accounted for 61.1%, which required more attention should be paidto the diagnosis and treatment of patients with heart failure of the ejection fraction remains.
文摘Objective： To carry out a systematic evaluation of the efficacy of modified Zhenwu Decoction combined withwestern medicine in the treatment of heart failure. Methods： Literature was retrieved in China KnowledgeResource Integrated Database （CNKI）, Chinese scientific journal database （VIP）, Wanfang Data Resource System（WANFANG DATA）, PubMed and other traditional Chinese medicine related periodicals by retrieval methods ofsubject terms combined with free words and computer retrieval combined with manual retrieval. Literature wasscreened strictly according to the inclusion criteria.The quality of the included literature was evaluated according tothe quality standard of Jadad scale and Cochrane collaboration network bias risk assessment tool. The literaturedata was extracted. RevMan5.3 software was used to analyze data and the curative effect of modified ZhenwuDecoction combined with western medicine was objectively evaluated. Results： The response rate of theexperimental group was better than that of the control group [OR = 3.69,95% IC （2.36,5.79）]. The value of EF inthe experimental group was higher than that in the control group after treatment [MD = 5.85, 95% IC （3.90, 7.79） ].The Lee, score of the experimental group was lower than that of the control group after treatment [MD = -1.37,95% IC （-2.23, -0.52） ]. The value of BNP in the experimental group was less than that in the control group aftertreatment [MD = -114.48, 95%IC （-186.28, -42.68）]. The life quality score in the experimental group was less thanthat of the control group after treatment [MD = -8.44, 95%IC （-11.73, -5.15）]. Conclusion： The curative effect ofmodified Zhenwu Decoction combined with western medicine in the treatment of heart failure is better than thesimple western medicine treatment.So modified Zhenwu Decoction combined with western medicine in thetreatment of heart failure is worthy of clinical promotion. However, the results of this study still need further validation by more high quality randomized double blind controlled clinical trial because the overall quality of theresearch included.
基金ThisworkwassupportedbyagrantfromtheGuangdongNatural ScienceFoundation (No .970 35 5 )
文摘Objective To study the urinary excretion of aquaporin-2 (AQP2) water channel protein, and the relationship between urine AQP2 concentration and renal AQP2 gene expression in chronic heart failure (CHF) rats. Methods Male Sprague-Dawley rats (200?g-250?g) underwent either a left coronary artery ligation, a model of CHF, or a sham-operation. Nine weeks after surgery, urinary AQP2 concentrations and renal AQP2 protein levels were measured by Western blot. Results The urinary concentration of AQP2 water channel protein increased significantly in CHF rats as compared with sham-operated rats (365.6%±102.9% vs 98.5%±47.6%, P<0.01). There was positive correlation between urinary AQP2 concentration and renal AQP2 protein expression (r=0.89, P<0.01). Conclusion The urinary concentration of AQP2 water channel protein increases significantly in chronic heart failure rats.
基金Shanxi Science and Technology Department(Grant No.2015011103)Shanxi Science and Technology Department(Grant No.201901D111343)“Research and development of Shanxi medicinal tea”of Shanxi University of traditional Chinese Medicine(Grant No.2020PY-YC-10)。
文摘In the present study, we aimed to explore the mechanism of Fu-Zi Decoction in the treatment of chronic heart failure(CHF) using network pharmacology. Sym Map database was used to analyze the modern medical(MM) symptoms of various medicines. The chemical components of Fu-Zi Decoction were obtained through TCMSP, ETCM database, and previous results. The targets of Fu-Zi Decoction were obtained through STITCH, Swiss Target Prediction, Target NET database, and literature. The targets for the treatment of CHF were obtained from the Dis Ge NET, GEO, and Drug Bank databases, and the common parts of the Fu-Zi Decoction targets were screened out to construct the PPI network. The PPI network was decomposed modularly, its functions were analyzed, and the KEGG pathway enrichment analysis was performed. The key target was verified by Swiss Dock for molecular docking. A total of 205 chemical components of Fu-Zi Decoction, 551 drug targets, and 521 disease targets were collected. Functional enrichment analysis revealed that it was mainly involved in biological processes, such as negative regulation of cell death, oxidative stress, and G protein-coupled receptor regulation. KEGG enrichment findings mainly involved fluid shear stress and atherosclerosis, IL-17 signaling pathway, and so on. The results of molecular docking showed that benzoylaconitine, aconitine, mesaconitine, paeoniflorin, and atractylodes Ⅲ all had a strong affinity with the core target CXCL8, suggesting that Fu-Zi Decoction could negatively regulate cell apoptosis and oxidative stress through fluid shear stress and atherosclerosis, IL-17 signaling pathway, and so on. Collectively, our data showed that Fu-Zi Decoction had a good effect on the treatment of CHF.
